Mirum Pharmaceuticals
Open
$97.22
Prev. Close
$97.24
High
$97.26
Low
$97.22
Market Snapshot
$4.84B
-207.2
-1.85
$336.89M
369
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 369 full-time employees. The company went IPO on 2019-07-18. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). Its clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Livmarli is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with ALGS in the United States and other countries.
Mirum Pharmaceuticals' brelovitug demonstrates significant antiviral efficacy against hepatitis delta, with Phase 3 trial results expected by late 2026, potentially advancing treatment options in this area.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 369 full-time employees. The company went IPO on 2019-07-18. Its commercial portfolio includes LIVMARLI (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM (cholic acid) for bile-acid synthesis disorders, and CTEXLI (chenodiol) for cerebrotendinous xanthomatosis (CTX). Its clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS). Livmarli is an orally administered, minimally absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with ALGS in the United States and other countries.
Recently from Cashu
Mirum Pharmaceuticals Strengthens Workforce with Inducement Awards for Rare Disease Commitment
Mirum Pharmaceuticals Enhances Workforce with Inducement Awards Amidst Commitment to Rare Disease Treatment Mirum Pharmaceuticals, Inc., a biopharmaceutical company based in Foster City, California, a…
Mirum Pharmaceuticals Expands Workforce to Boost Rare Disease Treatment Initiatives
Mirum Pharmaceuticals Strengthens Workforce to Enhance Rare Disease Treatment Initiatives Mirum Pharmaceuticals, Inc., a biopharmaceutical company based in Foster City, California, takes a significant…
Mirum Pharmaceuticals Charts Ambitious Growth Strategy for 2024 and Future Expansion
Mirum Pharmaceuticals Sets Ambitious Growth Path for 2024 and Beyond Mirum Pharmaceuticals, Inc., based in Foster City, California, outlines its strategic vision for 2024, forecasting robust growth dr…
Mirum Pharmaceuticals Targets Growth with LIVMARLI and Expanding Rare Disease Pipeline
Mirum Pharmaceuticals Charts a Growth Path for 2024 and Beyond Mirum Pharmaceuticals, Inc., a California-based biotechnology company, outlines a robust growth strategy for 2024, emphasizing significan…